These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33491528)

  • 61. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
    Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
    Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
    Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver.
    Yao J; Zhi M; Gao X; Hu P; Li C; Yang X
    Braz J Med Biol Res; 2013 Mar; 46(3):270-7. PubMed ID: 23532271
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Plasma adiponectin is decreased in nonalcoholic fatty liver disease.
    Pagano C; Soardo G; Esposito W; Fallo F; Basan L; Donnini D; Federspil G; Sechi LA; Vettor R
    Eur J Endocrinol; 2005 Jan; 152(1):113-8. PubMed ID: 15762194
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
    Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
    Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Combined Intervention with Germinated Vigna radiata and Aerobic Interval Training Protocol Is an Effective Strategy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Other Alterations Related to the Metabolic Syndrome in Zucker Rats.
    Kapravelou G; Martínez R; Nebot E; López-Jurado M; Aranda P; Arrebola F; Cantarero S; Galisteo M; Porres JM
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28753963
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
    Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
    Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice.
    Sahin E; Bagci R; Bektur Aykanat NE; Kacar S; Sahinturk V
    J Food Biochem; 2020 Jun; 44(6):e13194. PubMed ID: 32189355
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children.
    El-Koofy NM; Anwar GM; El-Raziky MS; El-Hennawy AM; El-Mougy FM; El-Karaksy HM; Hassanin FM; Helmy HM
    Saudi J Gastroenterol; 2012; 18(1):44-9. PubMed ID: 22249092
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Triterpenic acids-enriched fraction from Cyclocarya paliurus attenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3β pathway.
    Zheng X; Zhao MG; Jiang CH; Sheng XP; Yang HM; Liu Y; Yao XM; Zhang J; Yin ZQ
    Phytomedicine; 2020 Jan; 66():153130. PubMed ID: 31790897
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial.
    Pervez MA; Khan DA; Slehria AUR; Ijaz A
    Complement Ther Med; 2020 Aug; 52():102494. PubMed ID: 32951743
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
    Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
    Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis.
    Xiao F; Gao F; Zhou S; Wang L
    Medicine (Baltimore); 2020 Oct; 99(40):e22249. PubMed ID: 33019400
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Authors' response re. "May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?".
    Kalopitas G; Germanidis G; Chourdakis M
    Nutrition; 2022 Jun; 98():111510. PubMed ID: 34772595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.